Atossa Genetics’s endoxifen programs are advancing in their respective breast health programs. The firm recently reported positive safety data from its Phase I study on topical endoxifen in men, and it completed enrolment for its Phase II endoxifen study in women with elevated mammographic breast density (MBD). It is also advancing an oral endoxifen formulation in women refractory to tamoxifen, and is applying its intraductal microcatheter (IDMC) with cancer drug fulvestrant. Our rNPV-d
07 Dec 2018
Atossa Genetics - Multiple opportunities to address breast health
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Atossa Genetics - Multiple opportunities to address breast health
Atossa Therapeutics, Inc. (ATOS:NAS) | 0 0 0.0%
- Published:
07 Dec 2018 -
Author:
Pooya Hemami -
Pages:
17
Atossa Genetics’s endoxifen programs are advancing in their respective breast health programs. The firm recently reported positive safety data from its Phase I study on topical endoxifen in men, and it completed enrolment for its Phase II endoxifen study in women with elevated mammographic breast density (MBD). It is also advancing an oral endoxifen formulation in women refractory to tamoxifen, and is applying its intraductal microcatheter (IDMC) with cancer drug fulvestrant. Our rNPV-d